[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601576":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":53,"id":56,"slug":30,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":30,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MyeloGen Germline Testing Group","EXPERIMENTAL","Enrolled participants will complete:\n\n* Baseline visit with questionnaires, educational video, and punch skin biopsy\n* Negative genetic test results notification via mail\n* Positive genetic results will be followed up by an appointment with a genetic counselor or physician\n* Post-results questionnaires\n* Follow up via medical records for up to 2 years from time of study consent.",[13],"Device: MyeloGen Gene Panel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MyeloGen Gene Panel","The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.",[9],[21],"Custom hereditary cancer gene panel",[23],{"name":24,"affiliation":5,"role":25},"Christopher R Reilly, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","407-443-6243",null,"Christopherr_reilly@dfci.harvard.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Boston","Massachusetts","02215","United States",{"type":40,"coordinates":41},"Point",[42,43],-71.05977,42.35843,{"lat":43,"lon":42},[46,48],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":47},"christopherr_reilly@dfci.harvard.edu",{"name":24,"role":25,"phone":30,"phoneExt":30,"email":30},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Christopher Reilly","Sponsor-Investigator",[54],{"name":55,"class":6},"Broad Institute of MIT and Harvard","100601576",false,"NCT07112287","Germline Testing for Predisposition to Myeloid Malignancies","MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies","MyeloGen","Inclusion Criteria:\n\n* Age of 18 years or older\n* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.\n* Ability to understand and provide a signed and completed consent document in English.\n\nExclusion Criteria:\n\n* Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.\n* Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies","ALL","18 Years",{"count":66,"type":67},200,"ESTIMATED","INTERVENTIONAL",[70],"NA","The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.",[73,74,75],"Myeloid Malignancy","Genetic Predisposition to Disease","Myeloid Hematological Malignancies",[77,74],"Myeloid Malignancies","2026-04-21",{"date":80,"type":81},"2026-04-24","ACTUAL",{"date":83,"type":81},"2025-11-10",{"date":85,"type":67},"2033-04-01",{"name":51,"class":6},1]